SOURCE: NICOX
SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 28, 2010) –
TO: Investors, Analysts and Journalists
WHAT: NicOx S.A. will release its 2010 half year financial results on July
30 before the opening of the market trading in France and will host a
conference call at 3:00 pm CET.
WHO: Michele Garufi, Chairman and CEO
Eric Castaldi, Chief Financial Officer
Gavin Spencer, VP Business Development
WHEN: Friday July 30 – 3:00 pm CET (2:00 pm UK – 9:00 am EST)
Phone number: +44 (0)20 7138 0845 or +1 212 444 0895 (for conference call
and Q&A session).
A presentation will be available on NicOx’s website: www.nicox.com.
A replay of the conference call will be available from July 30 at 6:00 pm
CET until August 6 midnight. To listen to the replay, dial +44 (0) 20 7111
1244 or +1 347 366 9565 – Access code: 3771435?
Thanks to confirm your participation to Irène Lalande, Investor and
Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / [email protected]
The Company notably draws the investors’ attention to the following risk
factors:
– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)
– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)
– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)
– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)
– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.
NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).
In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.
NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).
This information is provided by HUGIN